These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19900396)

  • 1. Application of 19F magnetic resonance to study the efficacy of fluorine labeled drugs in the three-dimensional cultured breast cancer cells.
    Bartusik D; Tomanek B
    Arch Biochem Biophys; 2010 Jan; 493(2):234-41. PubMed ID: 19900396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of fluorine labeled herceptin using cellular (19)F MRI ex vivo.
    Bartusik D; Tomanek B
    J Pharm Biomed Anal; 2010 Mar; 51(4):894-900. PubMed ID: 19896315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined treatment of human MCF-7 breast carcinoma with antibody, cationic lipid and hyaluronic acid using ex vivo assays.
    Bartusik D; Tomanek B; Lattová E; Perreault H; Fallone G
    J Pharm Biomed Anal; 2010 Jan; 51(1):192-201. PubMed ID: 19709839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT; Metz MZ; Kane SE
    Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
    Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C
    Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
    Fan YX; Luo RC; Fang YX; Yan X; Lu CW
    Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI.
    Chen TJ; Cheng TH; Chen CY; Hsu SC; Cheng TL; Liu GC; Wang YM
    J Biol Inorg Chem; 2009 Feb; 14(2):253-60. PubMed ID: 18975017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.
    Nagy P; Friedländer E; Tanner M; Kapanen AI; Carraway KL; Isola J; Jovin TM
    Cancer Res; 2005 Jan; 65(2):473-82. PubMed ID: 15695389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Herceptin resistance in breast cancer cells.
    Kute T; Lack CM; Willingham M; Bishwokama B; Williams H; Barrett K; Mitchell T; Vaughn JP
    Cytometry A; 2004 Feb; 57(2):86-93. PubMed ID: 14750129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Killing effect of 131I-Herceptin on breast cancer cell lines in vitro].
    Lin J; Luo RC; Li AM; Zhang JY; Lü CW; Yan X
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):663-6. PubMed ID: 15958303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
    Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The application of 19F magnetic resonance ex vivo imaging of three-dimensional cultured breast cancer cells to study the effect of delta-tocopherol.
    Bartusik D; Tomanek B; Siluk D; Kaliszan R; Fallone G
    Anal Biochem; 2009 Apr; 387(2):315-7. PubMed ID: 19454246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorine-19 MRI at 21.1 T: enhanced spin-lattice relaxation of perfluoro-15-crown-5-ether and sensitivity as demonstrated in ex vivo murine neuroinflammation.
    Waiczies S; Rosenberg JT; Kuehne A; Starke L; Delgado PR; Millward JM; Prinz C; Dos Santos Periquito J; Pohlmann A; Waiczies H; Niendorf T
    MAGMA; 2019 Feb; 32(1):37-49. PubMed ID: 30421250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative
    Vernikouskaya I; Pochert A; Lindén M; Rasche V
    MAGMA; 2019 Feb; 32(1):25-36. PubMed ID: 30097741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo assays of CEM cells cultured and treated in the three dimensional cultures.
    Bartusik D; Tomanek B; Lattová E; Perreault H; Fallone G
    Biomed Pharmacother; 2010 Jul; 64(6):390-5. PubMed ID: 20347572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.
    Narayan M; Wilken JA; Harris LN; Baron AT; Kimbler KD; Maihle NJ
    Cancer Res; 2009 Mar; 69(6):2191-4. PubMed ID: 19276389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.